Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors

Clinical and Experimental Medicine

Volumn 11, Issue 1, 2011, Pages 55-59

  Manrique Arechavaleta, Gonzalo ^a   Scholl, Vanesa ^b   Pérez, Verónica ^a   Bittencourt, Roberta ^b   Moellmann, Arthur ^b   Hassan, Rocio ^b   Seuánez, Héctor N ^b   Dobbin, Jane ^b   Martinez, Lem ^a   Renault, Ilana Zalcberg ^b   Uriarte, Rosario ^a  

^a Specialized Techniques Laboratory   (Uruguay)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

AS RT PCR; BCR ABL; Chronic myeloid leukemia; Kinase domain mutations

Indexed keywords

BCR ABL PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ACCURACY; ALLELE SPECIFIC REAL TIME POLYMERASE CHAIN REACTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DILUTION; GENE SEQUENCE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ALLELES; AMINO ACID SUBSTITUTION; CLINICAL LABORATORY TECHNIQUES; DRUG RESISTANCE; EARLY DIAGNOSIS; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION, MISSENSE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCR; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 79951946395     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-010-0101-x     Document Type: Article

References (14)

1. D Marin D Milojkovic E Olavarria JS Khorashad H de Lavallade AG Reid L Foroni K Rezvani M Bua F Dazzi J Pavlu M Klammer JS Kaeda JM Goldman JF Apperley 2008 European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood 112 4437 4444 1:CAS:528:DC%2BD1cXhsVCltbzF 10.1182/blood-2008-06-162388 18716134
2. S Branford Z Rudzki I Parkinson A Grigg K Taylor JF Seymour S Durrant P Browett AP Schwarer C Arthur J Catalano MF Leahy R Filshie K Bradstock R Herrmann D Joske K Lynch T Hughes 2004 Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood 104 2926 2932 1:CAS:528:DC%2BD2cXpslKjurc%3D 10.1182/blood-2004-03-1134 15256429 (Pubitemid 39434981)
3. Branford S (2007) Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program Book 376-383
4. H Kantarjian C Schiffer D Jones J Cortes 2008 Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods Blood 15 1774 1779 10.1182/blood-2007-09-110189 (Pubitemid 351451481)
5. D Milojkovic J Apperley 2008 State-of-the-art in the treatment of chronic myeloid leukaemia Curr Opin Oncol 20 112 121 1:CAS:528:DC%2BD2sXhtlGns73N 10.1097/CCO.0b013e3282f1fe8a 18043265 (Pubitemid 350190990)
6. S Branford Z Rudzki S Walsh I Parkinson A Grigg J Szer K Taylor R Herrmann JF Seymour C Arthur D Joske K Lynch T Hughes 2003 Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood 102 276 283 1:CAS:528:DC%2BD3sXltFemu7k%3D 10.1182/blood-2002-09-2896 12623848 (Pubitemid 36759665)
7. SJ Clayton FM Scott J Walker K Callaghan K Haque T Liloglou G Xinarianos S Shawcross P Ceuppens JK Field JC Fox 2000 K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification Clin Chem 46 1929 1938 1:CAS:528: DC%2BD3cXoslyqtLs%3D 11106325
8. M Baccarani G Saglio J Goldman A Hochhaus B Simonsson F Appelbaum J Apperley F Cervantes J Cortes M Deininger A Gratwohl F Guilhot M Horowitz T Hughes H Kantarjian R Larson D Niederwieser R Silver R Hehlmann 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 1809 1820 1:CAS:528:DC%2BD28Xpsl2isrc%3D 10.1182/blood-2006-02-005686 16709930 (Pubitemid 44394987)
9. Scholl V, Bitencourt R, Pires V, Padilha T, Hassan R, Zalcberg IR (2008) Measurement of BCR-ABL transcripts in long-term allogeneic stem cell transplantation CML patients by real-time quantitative PCR (RQ-PCR). Haematologica 93(S1):540-541
10. IB Otazú I Zalcberg DG Tabak J Dobbin HN Seuánez 2000 Detection of BCR-ABL transcripts by multiplex and nested PCR in different haematological disorders Leuk Lymphoma 37 205 211 10.3109/10428190009057647 10721788 (Pubitemid 30142598)
11. S Branford Z Rudzki S Walsh A Grigg C Arthur K Taylor R Herrmann KP Lynch TP Hughes 2002 High frequency of point mutations clustered within the adenosine triphosphate binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 2475 3472 10.1182/blood.V99.9.3472 (Pubitemid 34525335)
12. SG Willis T Lange S Demehri S Otto L Crossman D Niederwieser EP Stoffregen S McWeeney I Kovacs B Park BJ Druker MW Deininger 2005 High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood 106 2128 2137 1:CAS:528:DC%2BD2MXhtVWksLvJ 10.1182/blood-2005-03- 1036 15914554 (Pubitemid 41291730)
13. T O'Hare CA Eide MW Deininger 2007 Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 110 2242 2249 10.1182/blood-2007-03-066936 17496200 (Pubitemid 47523141)
14. Soverini S, Poerio A, Vitale A, Gnani A, Colarossi S, Castagnetti F, Iacobucci I, Lonetti A, Palandri F, Rosti G, Amabile M, Paolini S, Papayannidis C, Gugliotta G, Vignetti M, Mandelli F, Baccarani M, Foà R, Martinelli G (2009) At the time of diagnosis, Ph + cells from both chronic phase myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations. Haematologica 94(suppl.2):212 (abs. 0526)